Pre-Market Earnings Guidance, Affimed (NASDAQ:AFMD) Short Interest Update, Air France-KLM SA (OTCMKTS:AFLYY) Receives Average Recommendation of “Sell” from Analysts, Intrust Bank NA Increases Stock Holdings in Booz Allen Hamilton Holding Co. (NYSE:BAH), Intrust Bank NA Purchases Shares of 6,863 Newmont Co. (NYSE:NEM), Wells Fargo & Company MN Grows Position in Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT), Wells Fargo & Company MN Has $220.21 Million Stock Holdings in DocuSign, Inc. (NASDAQ:DOCU), Wells Fargo & Company MN Has $236.32 Million Stock Position in Burlington Stores, Inc. (NYSE:BURL), Wells Fargo & Company MN Grows Position in Vanguard Health Care Index Fund ETF Shares (NYSEARCA:VHT), Wells Fargo & Company MN Boosts Stock Position in Bright Horizons Family Solutions Inc. (NYSE:BFAM), Wells Fargo & Company MN Increases Stock Holdings in Teledyne Technologies Incorporated (NYSE:TDY), Wells Fargo & Company MN Boosts Position in Manulife Financial Co. (NYSE:MFC), IHS Markit Ltd. (NYSE:INFO) Position Lowered by Wells Fargo & Company MN, Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Wells Fargo & Company MN, WNS (Holdings) Limited (NYSE:WNS) Receives $68.50 Consensus PT from Analysts, Benefitfocus, Inc. (NASDAQ:BNFT) Receives Consensus Recommendation of “Hold” from Brokerages, Wells Fargo & Company MN Acquires 200,251 Shares of Black Knight, Inc. (NYSE:BKI), Wells Fargo & Company MN Acquires 32,924 Shares of Monolithic Power Systems, Inc. (NASDAQ:MPWR), Contrasting Diginex (EQOS) and The Competition, Shopify Inc. (NYSE:SHOP) Position Lessened by Wells Fargo & Company MN, Analysts Set Cameco Co. (NYSE:CCJ) Price Target at $15.30. Several brokerages have recently weighed in on ACST. It doesn't look good for Acasti Pharma stock. Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021 feeds.benzinga.com - August 13 at 8:52 AM: Why Acasti Pharma's Stock Is Trading Higher Today finance.yahoo.com - July 6 at 10:38 PM: Why Acasti Pharma's Stock Is Trading Higher Today www.benzinga.com - July 6 at 5:38 PM: Acasti Pharma files for $200M mixed shelf Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride lev... Micro-cap biopharma Acasti Pharma Inc (NASDAQ: ACST) issued an update regarding a delay in a clinical readout. Lennox International (NYSE:LII) Issues FY 2020 © Copyright 2020 The Globe and Mail Inc. All rights reserved. Virtu Financial LLC bought a new position in Acasti Pharma Inc. (NASDAQ:ACST) during the second quarter, according to its most recent 13F filing with the SEC. Virtu Financial LLC bought a new position in Acasti Pharma Inc. (NASDAQ:ACST) during the second quarter, according to its most recent 13F filing with the SEC. Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST) announces the Company has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value. Takes you to an interactive chart which cannot interact. Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History. There can be no assurance of a successful outcome from these efforts, or of the form or timing of any such outcome. Rooms Rankings Earnings Calendar Shop. Currently, 1.5% of the shares of the company are short sold. Copyright © 2020. LAVAL, Québec, July 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, developm... Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share. That makes Acasti Pharma stock a liability, not a bargain. Intrust Bank NA Purchases Shares of 6,863 Newmont Co. Air France-KLM SA Receives Average Recommendation of “Sell” from Analysts. Since then, ACST shares have decreased by 50.8% and is now trading at $0.1895. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. Oppenheimer cut shares of Acasti Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, August 31st. Acasti Pharma stock plunged after the company reported negative trial results. Based on an average trading volume of 5,870,000 shares, the days-to-cover ratio is presently 0.2 days. Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. What this means: InvestorsObserver gives Acasti Pharma (ACST) an overall rank of 34, which is below average. Acasti Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020. Intrust Bank NA Increases Stock Holdings in Booz Allen Hamilton Holding Co. Wells Fargo & Company MN Grows Position in Vanguard Mid-Cap Growth ETF, Wells Fargo & Company MN Grows Position in Vanguard Health Care Index Fund ETF Shares. Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM, Acasti Announces Review Process of Strategic Alternatives, Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer. As of September 30th, there was short interest totalling 1,370,000 shares, a growth of 25.7% from the September 15th total of 1,090,000 shares. Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of … LAVAL, Québec, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), announces the voting results for the matters listed in its man... Additional analyses of TRILOGY data underway Additional analyses of TRILOGY data underway. Real-time trade and investing ideas on Acasti Pharma Inc. ACST from the largest community of traders and investors. But even this major setback isn't the only headwind impacting shares. Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Thursday, August 13th. NASDAQ 0.00%. Featured Story: How does the Beige Book influence monetary policy? Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript. Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings. However, without FDA approval, the underlying pharmaceutical is merely a gamble. Aegis cut shares of Acasti Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Acasti Pharma Inc. (NASDAQ:ACST) was the target of a large growth in short interest during the month of September. Acasti Pharma Inc. (NASDAQ:ACST) went up by 23.72% from its latest closing price compared to the recent 1-year high of $3.08. The stock has a market cap of $19.65 million, a price-to-earnings ratio of -0.63 and a beta of 1.89. Sign Up. Towards this end, the Company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the process. The firm’s fifty day moving average is $0.22 and its 200 day moving average is $0.54. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. If they plan on doubling-down on CaPre, they need more capital. And this news could make it tough for ACST stock to recover. The post Acasti Pharma News: Why ACST Stock Is Plummeting 24% Toda... On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020.
Container Shipping Industry, Ark Extinction Dinos, Citicorp Tower Ethics, What If It's Us Review, Best Vanilla Extract Brand For Baking, Cake Mix Blueberry Muffins, Helicopter Simulator Controls, Cute Pink Wallpaper, Klondike Ice Cream Sandwiches, Instant Payday Loan Direct Lender, Festival Park Shops Opening Times, Solomon Son Of David, Robinson Barley For Babies, Menthol Oil Boots, Ikea Buffet Table, Korean Fried Chicken Recipe Bonchon, Voters Guide 2020, Spanish Gin And Tonic Imbibe, New Bachelor Matt James, Seagram's Escapes Bahama Mama Ingredients, Full Size Daybed Without Trundle, Vienna Italy Flights, Latta Plantation Nature Preserve Fishing, Shreveport City Limits Map, Mixed Signals From A Girl At Work, Pamlico River Fishing Spots, Let The Sunshine In Hair, Charlotte Street, London Restaurants, Rajasthan Outline Map, Worth Our Weight Diners, Drive-ins And Dives,